Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
As part of the TARGET initiative, some disease groups have included various tumor or normal cell lines and/or xenografts as a means to test model systems available for research as well as determine proper tissue controls. TARGET has leukemia cell lines and xenografts, kidney tumor cell lines, normal brain tissues and embryonic stem cell lines. These data will serve as both comparators for TARGET diseases being studied and to further knowledge about the cell lines themselves. Additionally, in partnership with TARGET, some cell lines and xenografts from the NCI's Pediatric Preclinical Testing Program (http://pptp.nchresearch.org/index.html) will receive next generation sequencing, to include whole exome, and will have associated genomic data available through the TARGET Data Matrix once generated (http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html).
- Study Weblinks:
- Study Design:
- Tumor vs. Matched-Normal
- Study Type:
- Cohort
- Total number of consented subjects: 132
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data (Public ftp)
- Study Inclusion/Exclusion Criteria
Data is currently being generated for this substudy.
- Study History
Pediatric ALL and neuroblastoma were the first diseases to be piloted for the TARGET initiative, and ARRA funding allowed for its expansion to include pediatric AML, as well as osteosarcoma and kidney cancers. TARGET is jointly managed by the NCI Office of Cancer Genomics (OCG) and Cancer Therapy Evaluation Program (CTEP). The TARGET initiative is run as a cooperative collaboration between investigators and management staff at NCI, Children's Oncology Group, and multiple elite children's research hospitals and cancers centers throughout North and South America.
May, 2005 NCI and the American Cancer Society co-sponsor "Childhood Cancer Targeted Therapeutics Workshop" that ultimately served as a basis for the conception of TARGET. October, 2006 TARGET project officially initiated. January, 2009 First publication of characterization and analysis of 221 pediatric ALL patients from the pilot phase of TARGET. September, 2009 ARRA funding allows for expansion of TARGET pilot project to include additional cancers of study. - Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Antitumor Assay, Xenograft
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator (Cell Lines and Xenografts - PPTP)
- Peter Houghton, PhD. The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
-
NCI Program Officer
- Malcolm Smith, MD, PhD. National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator (Cell Lines and Xenografts - PPTP)